Osborne Clarke advised London listed Oxford Biomedica plc on the French law aspects of its acquisition of 100% of the shares of ABL Europe SAS from Institut Mérieux.
Oxford Biomedica is a world-leading cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in the UK, the EU and the US.
ABL Europe is a European CDMO specialised in viral vector development and manufacturing, with facilities in Lyon and Strasbourg. Focused on delivering GMP-compliant viral vectors from early-stage to market, ABL Europe plays a pivotal role in the success of client-focused gene and immunotherapy solutions.
The Osborne Clarke teams for Oxford Biomedica:
Lead – M&A: Catherine Olive, partner – Julie Dahan, senior associate – Anthony Chung, associate.
Employment Law : Jérôme Scapoli, partner – Maud Parssegny and Alexandra Mestrallet, associates.
Commercial, Life Sciences: Thomas Devred, partner – Justine Pellerin, associate.
IP/ IT/ Data: Xavier Pican, partner – Alice Vigne, associate.
Real estate: François-Régis Fabre-Falret, partner – Julia Gaspard, counsel.
Tax: Dorothée Chambon, partner – Clément Petit, senior associate – Aminata Sarre, associate.
Compliance law: Lucie Mongin-Archambeaud, partner – Lucie Champetier, associate.
Client relationship: Matthew Edwards, partner UK.
Corporate communications and press contacts
Connect with one of our experts
